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Introduction
Digital rectal examination (DRE), transrectal ultrasono graphy (TRUS) and prostate-specific antigen (PSA) are commonly used as diagnostic tools in the early detection of . None of these tests has sufficient accuracy to justify its use alone as a scree combination of DRE, TRUS and to predict the presence of carcinoma 11 ].
Although cancer in •es test. The ability is accurate mi for ; prostate, its sensitivity ; are insufficient. Consensus exists that for a PSA value < 4 ng/mL, where the incidence of prostate cancer is PSA may be found in patients with BPH or after prostatic manipulations such as cystoscopy and prostate biopsy half-life of PSA is estimated to be 2.2 [7] to 3.2 days it may, i on j rise m level, take 2 -3 weeks after prostatic manipulation before the PSA serum level has decreased to its base-line value.
Because prostatic volume may iniluence the PSA level it is prudent to make a correction for prostatic volume (PSA/prostatic volume = PS A-density, PSAD) as proposed by Benson et al. [9' J. An overview of the results of several studies is shown in Table 1 ; there is still much debate about the clinical value of PSAD.
According to Benson et ai 151, patients , a 1.4% sies are not i if there is no further PSAD < 0 .1 5 ng/mL/cm1 and a normal Dilli may be suspicion lbr malignancy. At a PSA level > 1 0 ng/mL, the incidence of prostate cancer is 53.3% (3 J and most authors [4,5] agree that biopsies have to be taken in these cases. In the range between 4 and 10 ng/mL PSA (intermediate PSA levels, i benign prostatic frequently occur in patients diagnosis is :rplasia as or prostate cancer iPSA. An increase m Accepted for publication 27 January 1995 treated by watchful waiting, as re is only an 18% chance of them having a positive biopsy. Bazinet el al.
also used a limit for PSAD of 0.1 5 ng/mL/cm1, below which only 3% of patients had a positive biopsy.
Ramon et al polyclonal Yang
Vc to equal to in their study but, conver of the Hybritech assay, and for a 0.15 ng/mL/cm3, they found a 42% incidence of prostate cancer in the PSA range of 1 .7 -6 .7 ng/mL and a 51% 48 M.P. VAN IERSEL et al Table 1 because they do not plane 3-D VRW 77AK) and were carried out by one provide enough data in the iPSA range.
To evaluate the clinical value of PSAD in the iPSA range, the correlations of PSAD, PSA, DRE and TRUS with the results of histopathological examination of Biopty gun (C.R. Bard, Covington, USA), using 18 G urologist experienced in performing TRUS. Prostatic volume was calculated using a planimetric method incor porated in the scanner. Biopsies were taken with the patients who underwent transrectal biopsies were retrospectively investigated. Increases in PSA also occur 'Tru-cut' biopsy needles. If a hypoechoic lesion was seen, a core was taken from that region. In 76% of the during acute prostatitis [19-21]. A histologically distinct patients, three cores were taken from the right and left feature of acute prostatitis is the invasion of white blood sides, equidistant from the base and apex, in 20% two cells into the prostatic ducts. These are predominantly cores were taken from each side of the prostate and in polymorphic, rather than mononuclear, white blood cells. This invasion may cause a leakage of PSA from the ductal lumina, as the integrity of the prostatic ducts is disturbed. Therefore, we investigated whether PSAD 4% only ultrasound-guided biopsies were taken. The cores were sectioned and stained with haematoxylin and eosin. On the basis of these sections patients were then assigned to either a benign or a malignant group. or PSA was significantly higher in patients for whom Analyses were performed on data from the whole group we had histological proof of extensive acute inflammation of the prostate.
Patients and methods
Between January 1991 and December .1993, transrectal and separately on the patients with iPSA. Additional analyses were performed using the PSA levels of patients with histologically proven extensive prostatitis.
Significance was evaluated using the Mann-Whitney U'test and the x2-tests. Receiver operator characteristic (ROC) curves, graphically representing the correlation biopsy of the prostate was performed in 376 men (mean between sensitivity and the false positive fraction, were age 69.1 years, range 48.4-97.5), till of whom had constructed to determine the optimal limits for PSA and micturition complaints.
Indications for biopsy were a suspect nodule on DRE,
PSAD. A perfect test would have a 100% sensitivity and a 0% false positive rate with an area under the curve of a hypoechogenic lesion on TRUS or a PSA value one. The usefulness of a diagnostic test is assessed by > 1 0 ng/mL. All patients underwent TRUS, DRE and
calculating the fractional area under the ROC curve. A had their serum PSA level determined using the multivariate analysis was also performed to assess the Tandem-E PSA assay (Hybritech, San Diego, CA, USA).
individual value of DRE, TRUS, PSA and PSAD in the No blood samples were used if they were taken within detection of prostate cancer. 2 weeks of acute urinary retention, within 3 weeks of 
Results

Total group
A moan of 6.1 cores per patient was taken for biopsy and in 71.6% of the patients at least six cores were taken. The histological examination revealed prostate cancer in 113 patients (Table 2) .
Five patients with an initial benign histology were biopsied again within 1 year and were proved to have prostate cancer. The second biopsy was performed because the initial histological diagnosis was suspect (two patients) or there was a rise in PSA level (three patients). These patients were reclassified as having a malignant tumour.
The mean PSA level was 9.6 ng/mL in the patients with a benign diagnosis and 3 3.0 ng/mL in those with malignancies. Although 95.6% of the patients in the benign group had a PSA < 7 8 ng/mL, there were two patients with BPH and a PSA level > 7 8 ng/mL. One patient with a PSA level of 190 ng/mL underwent transurethral resection of the prostate and 150 g of tissue was resected. Histological examination showed focal abscesses. The mean PSAD was 0..17 ng/mL/cm3 in the benign group and 0.91 ng/mL/cm5 in the malig nant group. The PSA level, prostate volume and PSAD were significantly different between the benign and the malignant group (P < 0.001). The area under the ROC curves for PSA (0.816) and PSAD (0.858) in the whole group were not significantly different (Fig. 1) . -0.1 31 ) . However, when TRl.IS showed no abnormality, DRE was able to differentiate between malignant and benign biops ies (P = 0.01.1). In the group with a normal DRE, both PSAD and the PSA level could differentiate between malignant and benign biopsies (Table 4 ).
In the benign group, 13 patients ( 3.5%) had biopsies but with moderate to extensive invasion of polymorphic white blood cells and the biopsies were histologically classified as prostatitis. There was no significant differ ence between the prostatitis group and the benign group but with no prostatitis in PSA level, prostate volume or PSAD (P= 0 .0 6 , P = 0 .0 6 and P = 0.47, respectively). DRE findings were more often classified as malignant in the prostatitis group than in the benign group (P=0.009), whereas TRUS did not differ between these One biopsy from a patient with a PSAD below this limit groups (P = 0.536).
iPSA Ninety-one patients had iPSA levels. A mean of 6.2 cores appeared to be malignant. Of the 79 benign biopsies 43 (54%) had a PSAD < 0.15 ng/mL/cm3. None of the 12 patients with a malignant biopsy had a PSAD < 0 .1 1 ng/mL/cm3 compared with 27 of the 79 benign biopsies (34%). The performance for different values of per patient were taken during biopsy and in 74.7% of PSAD is given in Table 5 . For some PSAD limits, sensithese patients six or more cores were taken. In 12 patients the biopsies appeared malignant and in 79 they were benign (Table 4) . PSAD was significantly different (P= 0,027) between the patients with a benign or a malignant histology but PSA level did not differ significantly (P= 0.316). ROC curves were plotted for PSA and PSAD (Fig. 2) giving an area under the curve of 0.59 for PSA and 0.70 for PSAD, which was significantly different, indicating that PSAD was superior to PSA in differen tiating between benign and malignant prostatism. tivity and specificity are given if these values were taken as the upper limit, below which the PSAD was a predictor of benign histology and above which malignant histology could be predicted. Table 6 gives the performance of DRE and TRUS in this group. DRE findings correlated well with the histological outcome (P = 0.004) while TRUS could not discriminate significantly between malignant and benign tissue (P = 0.300).
Discussion
The detection of early prostate cancer depends on the accuracy of DRE, TRUS and serum PSA, which are currently considered to be the best tools for the diagnosis Table 5 Performance of different PSAD limits in patients with PSA levels between 4.0 ng/mL and 10.0 ng/mL [15] found a value of 0.12 ng/mL/cm3. Some authors think that PSAD is of little or no value in discriminating between prostate cancer and 13PH and suggest that age-specific PSA values are more useful than PSAD [28]. As prostatic volume increases with age, a higher limit lor the lower threshold of the normal PSA of prostate cancer [3]. However, the accuracy of PSA in range in older men in itself implies a correction for higher prostate volumes in older men. differentiating patients with prostate cancer from those
The aim of this retrospective analysis was to investiwith benign disease is insufficient, according to some gate whether PSAD-based clinical guidelines could help authors [7, 25] . In the iPSA range there is an overlap of in the diagnosis of prostate cancer and assist in avoiding PSA levels in patients with prostate cancer and those a significant number of biopsies. In the study, most TRUS with benign disease.
was performed immediately after DRE. The subsequent PSAD promised to be a better tool in differentiating interpretation of TRUS can be biased, because the outbetween patients with BPH and prostate cancer [13]. All come of DRE (and PSA) may influence the interpretation but one of the studies mentioned in Table 1 confirmed the findings of Benson [5] that PSAD is superior to PSA in differentiating between benign and malignant pros-of the TRUS image. However, TRUS had no significant extra value when combined with DRE in the detection of prostate cancer (P = 0.131). Because all patients were tates in the iPSA range. A limit of 0.15 ng/mL/cm3 was referred for micturition complaints many in the benign chosen by these authors, but the choice of a threshold group inevitably presented with a high prostate volume. value of PSAD depends on the desired sensitivity for the detection of prostate cancer. A balance must be found This could explain the significantly volume in this group compared to prostate group with between an acceptable proportion of undetected prostate prostate cancer (Table 2) Overall, PSAD made no significantly better distinction The reliability of PSAD is a product of the reliability between patients with prostate cancer and those with of its constituents; the accuracy of PSAD obviously BPH . 1). In the iPSA range only 12.1% of the depends on the accuracy with which the PSA and patients appeared to have prostate cancer, which is the prostatic volume are assessed. The production of PSA lowest rate of the studies quoted in Table 1 , possibly per volume of prostatic tissue is not only related to the because the present study was comprised of patients presence of BPH and prostate cancer but also to the with micturition complaints. In this group, the mean proportion of epithelial cells and to the histological grade prostate volume was higher when compared to a screenof the carcinoma. Hormonal status and other factors may also play a role. Assessment of the prostatic volume ing population which may explain why these patients more often had a PSA value > 4 .0 ng/mL. depends on many factors and can be calculated by the In the iPSA range, the sensitivity was '100% and the or planimetrie methods. The calculation of specificity 32% for the diagnosis of prostate cancer when the prostatic volume in the first three articles listed in a PSAD limit of 0,11 ng/mL/cm1 was used. If a limit of Table 1 was made using the method (i.e. 0.1 5 ng/mL/cm3 was used the values were 92 and 54%, 0.52 x length x width x height). Stone et al.
[26] found respectively. No limit could be found that combined that step-section 3D-planimetry gave a variability of 5% a good sensitivity and a good specilicity (Table 5 ). compared with 30% for a three-axis method. According Moreover, of the 1.2 patients in this range who had to Holmang et al. [27] the ellipsoid method underesti-prostate cancer, 11 had a suspect DRE. This finding is mates the volume by 20%) compared with the planimetry not surprising, as patients with a normal DRE were only of several sections, but they are well correlated with biopsied if TRUS was abnormal and, as indicated, TRUS each other. The planimetrie method, as used in the is an inaccurate means of detecting early prostate cancer. present study, seems the most accurate.
PSAD was of no additional value to DRE in differentiating Moreover, one would expect that PSAD, calculated as between prostate cancer and benign disease in the iPSA range. This might be explained by selection of patients, as patients with an iPSA level, a normal TRUS and a normal DRE were not biopsied.
Conclusions
The PSAD limit chosen is not an absolute value as it depends on the population examined, the reliability of the measurement of prostatic volume and the desired sensi tivity. In patients with micturition complaints and an iPSA level, a PSAD <0.15 ng/mL/cm3 indicates a high probability (97.7%) of benign histology, but the PSAD is of limited additional value to DRE. Both PSA and PSAD had no significant value in differentiating between histologically proven extensive prostatitis and BPH.
